AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11731749
Drug: Mannitol 0.5
RxNorm normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 0.5 g.kg‐1 and Mannitol 0.25 g.kg‐1
Trial: 9165314
Drug: Objective group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective group (passing the 12 mm barium pill test)
Trial: 9165314
Drug: Pill test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill test (overall correlation)
Trial: 9165314
Drug: Passing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passing the pill test 1 week after dilation
Trial: 9165314
Drug: Failing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failing the pill test
Trial: 3593990
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens with tamoxifen 20 mg bid for patients with positive estrogen receptor status
Trial: 28104469
Drug: 3-month intensive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month intensive lifestyle intervention consisting of weekly health education and 3 moderate-to-vigorous physical activity sessions/week
Trial: 26206644
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo injection)
Trial: 2537787
Drug: Kabi 2165,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kabi 2165, 2,500 anti‐Xa units twice a day (group A)
Trial: 2537787
Drug: Kabi 2165,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kabi 2165, 2,500 anti‐Xa units twice a day during the first 48 h postoperatively and then 5,000 anti‐Xa units once a day (group B)
Trial: 2537787
Drug: Adjusted-dose standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose standard heparin, monitored by activated partial thromboplastin time (group C)
Trial: 31850603
Drug: Nicotine-replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine-replacement therapy (NRT)
Trial: 29099972
Drug: Subanesthetic dose
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic dose of ketamine
Trial: 26665676
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dapoxetine on demand
Trial: 26665676
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sertraline qd for one month
Trial: 23702146
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling plus administration of a commercially available Ca(2+) and VitD supplementation product
Trial: 11396283
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume BAL (mean volume: 131 +/- 14 ml)
Trial: 11396283
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume BAL (40 ml volume for all patients)
Trial: 8143994
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran supplement (13-15 g for 8 weeks)
Trial: 8143994
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran supplement (13-15 g for 8 weeks)
Trial: 8143994
Drug: Corn bran
RxNorm normalized name: CORN BRAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn bran supplement (13-15 g for 8 weeks)
Trial: 2306750
Drug: Flunarizine 10-15
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 10-15 mg (mean dose of 13 mg)
Trial: 2306750
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg (single dose)
Trial: 6254720
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intravenous clonidine after pretreatment with 300 mg cimetidine
Trial: 6254720
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intravenous clonidine after pretreatment with 0.8 mg naloxone
Trial: 6254720
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intravenous clonidine after pretreatment with saline
Trial: 27224454
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART) regimens for prevention of mother-to-child transmission during breastfeeding
Trial: 25012765
Drug: Risperidone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (6 mg/day in 3 divided doses) + Raloxifene (120 mg/day)
Trial: 25012765
Drug: Risperidone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (6 mg/day in 3 divided doses) + Placebo
Trial: 17909753
Drug: Butorphanol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0, 6, or 12 mg/70 kg, i.m.)
Trial: 17909753
Drug: Naltrexone (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (0, 1, 3, 10, or 30 mg, p.o.)
Trial: 16441799
Drug: lignocaine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 5% spray
Trial: 1451713
Drug: DoBe (L-Dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DoBe (L-Dopa + benserazide)
Trial: 1451713
Drug: DoBeBro (L-Dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DoBeBro (L-Dopa + benserazide + bromocriptine)
Trial: 28717702
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine once per day
Trial: 18645193
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1,000 mg)
Trial: 15909176
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) - 3000 shocks of 0.20 mJ/mm(2)
Trial: 12877888
Drug: Aprotinin (APRO)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (APRO) at a low dose of 2 Mio KIU in the priming volume
Trial: 10360185
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy with a protease inhibitor
Trial: 10360185
Drug: No multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No multidrug therapy with a protease inhibitor
Trial: 7740525
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs (3.4 g eicosapentaenoic and docosahexaenoic acids per day) for six months
Trial: 2139385
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg/die)
Trial: 7234470
Drug: brief care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brief care (acute treatment aimed at effecting the patient's discharge after about a week)
Trial: 29803597
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser vaporization (L group)
Trial: 22136068
Drug: NVP XR
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP XR 400 mg once daily
Trial: 22136068
Drug: NVP IR
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP IR 200 mg twice daily
Trial: 17966175
Drug: Dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel 5% applied twice daily for up to 12 months
Trial: 17966175
Drug: Dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel 5%
Trial: 10334524
Drug: Single-agent drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent drugs (trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin) followed by CAF
Trial: 10334524
Drug: Single-agent drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent drugs followed by CAF
Trial: 8305994
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive drug therapy
Trial: 8305994
Drug: Moderate antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate antihypertensive drug therapy
Trial: 8960857
Drug: Nisoldipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (calcium channel blocker)
Trial: 8960857
Drug: Enalapril (angiotensin‐converting‐enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (angiotensin‐converting‐enzyme inhibitor)
Trial: 8960857
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive therapy
Trial: 8960857
Drug: Moderate antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate antihypertensive therapy
Trial: 19589241
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg/day)
Trial: 6761595
Drug: CD combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD combination
Trial: 30415307
Drug: Awareness Index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness Index of antibiotic resistance
Trial: 30415307
Drug: Antibiotic conservation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic conservation practices
Trial: 26691608
Drug: School-based child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based child oral hygiene program
Trial: 24067296
Drug: Digoxin 0.125
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.125 mg/day
Trial: 24067296
Drug: Digoxin ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin ≥ 0.25 mg/day
Trial: 20854139
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of ≥1 hypertension medications
Trial: 20854139
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (all medications ingested upon awakening)
Trial: 9596232
Drug: Regular alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular alcohol intake (<50 g/d)
Trial: 9596232
Drug: Heavy alcohol
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy alcohol consumption (>=100 g/d)
Trial: 7508804
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost for 6 h per day over 14-21 days
Trial: 30111378
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment
Trial: 7508804
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost
Trial: 3128439
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (3 mg/h)
Trial: 720134
Drug: Urea preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea preparations under occlusive dressings
Trial: 27356083
Drug: DHA 20
RxNorm normalized name: DHA 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA 20 mg/kg/d + ARA 40 or 60 mg/kg/d + ARA 120 mg/kg/d
Trial: 21584922
Drug: Intensive subcutaneous
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive subcutaneous insulin protocol
Trial: 21584922
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with sliding scale insulin
Trial: 20215786
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with etoposide, Adriamycin and cisplatin (EAP)
Trial: 20215786
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with EAP
Trial: 17469888
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment as usual
Trial: 15960083
Drug: Tactile signals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile signals administered to the treatment group to indicate the arrival and location of interrupting tasks.
Trial: 12360175
Drug: Both atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both atorvastatin and fenofibrate
Trial: 10432959
Drug: Etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 400 mg per day for 14 days followed by 500 mg calcium carbonate per day for 76 days, repeated for one year
Trial: 6936978
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen) immediately preseasonal
Trial: 6936978
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Trial: 6936978
Drug: 18 injections
RxNorm normalized name: quaternium-18
DrugBank: Quaternium-18 (DB11305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 injections of a 7 grass pollen extract (semi‐depot, Allpyral)
Trial: 6936978
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of a tyrosine adsorbed grass pollen vaccine (Pollagen)
Trial: 28624819
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin 2 g
Trial: 24680234
Drug: Brief, 5-session,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief, 5-session, problem-focused couple therapy for depression
Trial: 17236918
Drug: Intravenous prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prophylactic antibiotics (penicillin or clindamycin for penicillin-allergic subjects)
Trial: 15051598
Drug: 70 g
RxNorm normalized name: alcohol .70 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 g MCTs (66% 8:0 and 34% 10:0)
Trial: 10535880
Drug: Interferon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (3 MU 3 times weekly) for 24 months
Trial: 10535880
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of interferon
Trial: 7594123
Drug: Cholesterol-lowering diets
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering diets (30%, 26%, 22%, and 18% of energy from fat; 300, 200, 100, and 100 mg cholesterol)
Trial: 1099895
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment
Trial: 29334292
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy (3 sessions, 60 min each)
Trial: 27194235
Drug: Colonic irrigation
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic irrigation using the Ashong colonic irrigation apparatus (ACIA), performed twice daily for 6 consecutive days per week for 1-4 weeks.
Trial: 22116114
Drug: Higher class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher class pain medication
Trial: 20205646
Drug: Cyclooxygenase-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclooxygenase-2 inhibitors
Trial: 7606425
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation (IDEOS) containing 500 mg calcium and 400 IU vitamin D3, taken as one tablet twice daily for six months
Trial: 7606425
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of 8 drops of vitamin D3 (800 IU/day) and one calcium carbonate 500 mg tablet twice daily for six months
Trial: 91886
Drug: Intramuscular iodised
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iodised oil
Trial: 30985694
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral rectus sheath block (RSB) using 40 mL of 0.375% ropivacaine
Trial: 30985694
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving RSB using 40 mL of normal saline
Trial: 16487501
Drug: PCIA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA using morphine
Trial: 12620951
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 micro g x kg(‐1) iv followed by a continuous infusion of 0.2 to 0.5 micro g x kg(‐1) x min(‐1))
Trial: 12620951
Drug: Nitroprusside (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside (0.25 micro g x kg(‐1) x min(‐1) iv and alfentanil iv)
Trial: 9345173
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with high energy groundnut biscuits (4.3 MJ/day) for about 20 weeks before delivery
Trial: 8155388
Drug: Toremifene 60
RxNorm normalized name: toremifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 60 mg
Trial: 8155388
Drug: Toremifene 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 300 mg
Trial: 24997863
Drug: Rg3-enriched Korean
RxNorm normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rg3-enriched Korean red ginseng (400 mg)
Trial: 24997863
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (400 mg)
Trial: 22081263
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) 500 mcg every 3 weeks (Q3 W) or 2.25 mcg/kg DA weekly (QW) for 15 weeks
Trial: 19929694
Drug: Ad5 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5 vaccine alone
Trial: 16188181
Drug: KTP 532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTP 532 nm laser treatment
Trial: 12359987
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication (Nitrendipine, Atenolol, Captopril)
Trial: 7259925
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg/day
Trial: 7259925
Drug: Cimetidine 1600
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1600 mg/day
Trial: 7259925
Drug: Cimetidine pharmacokinetics
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine pharmacokinetics
Trial: 21239090
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein (HP) diet (3.0 g protein/kg BW) for 3 weeks
Trial: 21239090
Drug: Usual Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Protein (UP) diet (1.5 g protein/kg BW) for 3 weeks
Trial: 15330150
Drug: steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroids and oral magnesium
Trial: 15330150
Drug: steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroids and placebo
Trial: 7740465
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyloestradiol combination
Trial: 7740465
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms ethinyloestradiol combination
Trial: 2965633
Drug: ANP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP with background infusion of ANG II
Trial: 24131567
Drug: Exposure Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure Group Therapy (EGT)
Trial: 17625032
Drug: 5 mW
RxNorm normalized name: POLYETHYLOXAZOLINE (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mW laser irradiation (650 nm), applied transmeatally for 15 minutes, once daily for a week
Trial: 10627439
Drug: Syndecan-1 elevated
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syndecan-1 elevated in patients (median, 643 units/mL)
Trial: 10627439
Drug: Syndecan-1 dichotomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndecan-1 dichotomized by best cutoff (66th percentile, 1170 units/mL)